Phenotyping Patients with Chronic Obstructive Pulmonary Disease and Heart Failure
COPD was present in every eight patient with HF, and more common with preserved EF. Patients with COPD had more severe HF, heavier comorbidity burden and worse morbidity/mortality regardless of EF. Our results call for improved diagnostic and management strategies in patients with HF and COPD.
Authors
- Gianluigi Savarese (ORCID: https://orcid.org/0000-0001-7732-0887)
- Lina Benson
- Stefan Blankenberg (ORCID: https://orcid.org/0000-0001-6488-2362)
- Paulus Kirchhof (ORCID: https://orcid.org/0000-0002-1881-0197)
- Stephan Rosenkranz (ORCID: https://orcid.org/0000-0001-6237-1470)
- Frieder Braunschweig (ORCID: https://orcid.org/0000-0002-4966-1315)
- Lars H. Lund (ORCID: https://orcid.org/0000-0003-1411-4482)
- Francesco Cosentino (ORCID: https://orcid.org/0000-0002-6967-5685)
- Felix Lindberg (ORCID: https://orcid.org/0000-0002-7380-9877)
- Ulf Dahlström (ORCID: https://orcid.org/0000-0001-6353-8041)
- Camilla Hage (ORCID: https://orcid.org/0000-0002-4142-2416)
- Giuseppe M.C. Rosano
- Peter Moritz Becher (ORCID: https://orcid.org/0000-0003-1221-7015)
Institutions
- Linköping University (SE)
- Karolinska University Hospital (SE)
- Universität Hamburg (DE)
- University of Cologne (DE)
- Università degli studi di Cassino e del Lazio Meridionale (IT)
- Sandwell & West Birmingham Hospitals NHS Trust (GB)
- Karolinska Institutet (SE)
- University Medical Center Hamburg-Eppendorf (DE)
- German Centre for Cardiovascular Research (DE)
- University Hospital Cologne (DE)
- University of Birmingham (GB)
Publication Details
- Journal
- ESC Heart Failure
- Published
- 2024-11-07
- DOI
- https://doi.org/10.1002/ehf2.15127
- Citations
- 9
- Primary Topic
- Heart Failure Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 3.62
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Teva Pharmaceutical Industries
- United Therapeutics Corporation
- Boston Scientific Corporation
- Cytokinetics
- MyoKardia
- Singulex
- British Heart Foundation
- European Commission
- Deutsche Forschungsgemeinschaft
- Fondation Leducq
- Novo Nordisk
- Universität Hamburg
- Servier
- Abbott Diagnostics
- Medical Research Council
- Relypsa